Core Points - The company Eliem Therapeutics, Inc. has changed its name to Climb Bio, Inc. to reflect its new focus on developing treatments for immune-mediated diseases following the acquisition of Tenet Medicines, Inc. [1][2] - Climb Bio will begin trading on Nasdaq under the new ticker symbol "CLYM" effective October 3, 2024 [1] - The lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody with potential applications in various B-cell mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy [2][4] Company Strategy - The name change and rebranding aim to symbolize the journey of patients with autoimmune diseases and the commitment to developing new treatments [2] - The company has refreshed its corporate website and adopted a new logo to align with its strategic direction [3] Product Development - Budoprutug, previously known as TNT119, is designed to deplete CD19-positive B cells, which may lead to a reduction in pathogenic autoantibodies [2] - In a Phase 1b clinical trial for membranous nephropathy, 60% of patients receiving four doses of budoprutug achieved complete remission of proteinuria [2]
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.